Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma

NCT07104032 is registered in ClinicalTrials.gov with Ono Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07104032
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07104032 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants With Relapsed/Refractory Primary Central Nervous System Lymphoma
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 12, 2026
Completion date
December 31, 2029
Enrollment
132 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory primary central nervous system lymphoma